Study title:
Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha
Long title:
Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esophageal squamous cell carcinoma or bladder carcinoma
Date receipt dossier:
26 Mar 1998
Pharmaceutical study code:
MEL01198
Company / Sponsor:
Pasteur Mérieux Connaught
Phase:
I
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
Malignant melanoma, Non-Small Cell Lung Cancer, Squamous cell carcinoma of the Head and Neck, Bladder transitional cell carcinoma
Therapeutic approach:
Immunotherapy
Genetic modification:
HLA-A1 restricted CTL epitope of MAGE-1 and
MAGE-3 genes
Method of transfer of nucleic acid of interest:
Canarypox Virus (ALVAC)
Administered biological material:
Recombinant Canarypox Virus
Route of administration:
Subcutaneous
Locations in Belgium:
Cliniques Universitaires St-Luc, Brussels
Type of procedure:
Contained use only
Current status:
Authorized